Regorafenib

GIST

Institut BergoniéSmall moleculePhase 4 / ApprovedDormant

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 63/ 100
Competitive Position: 89/ 100

Competitive context

12 Active assets in the GIST cohort.

Asset / Sponsor	Phase	Rating
MIDAZOLAM Blueprint Medicines Corporation	Phase 4	BBB
Esomeprazole Erasmus Medical Center	Phase 4	BB
Imatinib M.D. Anderson Cancer Center	Phase 2	BB
CAFFEINE Markus Joerger	Phase 4	BB
Avapritinib Blueprint Medicines Corporation	Phase 3	BB

View all 50 →

Same molecule, other indications

Regorafenib is also rated in:

colorectal neoplasmDormant

BB

Indicative ·

71 / 100

RegorafenibDormant

BB

Indicative ·

70 / 100

colorectal cancerDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.